China Resources Pharmaceutical Group Limited (3320.HK)
HKD 5.46
(-0.18%)
HKD 5.46
(-0.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 29.35 Billion HKD | 7.48% |
| 2022 | 28.32 Billion HKD | 8.38% |
| 2021 | 26.13 Billion HKD | 9.69% |
| 2020 | 23.82 Billion HKD | -8.35% |
| 2019 | 25.99 Billion HKD | 11.7% |
| 2018 | 23.26 Billion HKD | 30.16% |
| 2017 | 17.87 Billion HKD | 24.94% |
| 2016 | 14.3 Billion HKD | 7.68% |
| 2015 | 13.28 Billion HKD | 1.85% |
| 2014 | 13.04 Billion HKD | 7.86% |
| 2013 | 12.09 Billion HKD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 15.11 Billion HKD | 0.0% |
| 2023 Q4 | 15.49 Billion HKD | 0.0% |
| 2023 FY | 30.44 Billion HKD | 7.48% |
| 2023 Q2 | 15.3 Billion HKD | 0.0% |
| 2022 Q2 | 13.2 Billion HKD | 0.0% |
| 2022 FY | 28.32 Billion HKD | 8.38% |
| 2022 Q4 | 15.11 Billion HKD | 0.0% |
| 2021 Q2 | 12.05 Billion HKD | 0.0% |
| 2021 Q4 | 14.07 Billion HKD | 0.0% |
| 2021 FY | 26.13 Billion HKD | 9.69% |
| 2020 FY | 23.82 Billion HKD | -8.35% |
| 2020 Q4 | 13.97 Billion HKD | 0.0% |
| 2020 Q2 | 9.85 Billion HKD | 0.0% |
| 2019 Q2 | 11.95 Billion HKD | 0.0% |
| 2019 FY | 25.99 Billion HKD | 11.7% |
| 2019 Q4 | 14.03 Billion HKD | 0.0% |
| 2018 FY | 23.26 Billion HKD | 30.16% |
| 2018 Q2 | 10.49 Billion HKD | 0.0% |
| 2018 Q4 | 12.77 Billion HKD | 0.0% |
| 2017 FY | 17.87 Billion HKD | 24.94% |
| 2017 Q2 | 7.22 Billion HKD | 0.0% |
| 2017 Q4 | 10.65 Billion HKD | 0.0% |
| 2016 FY | 14.3 Billion HKD | 7.68% |
| 2016 Q4 | 7.6 Billion HKD | 0.0% |
| 2016 Q2 | 6.7 Billion HKD | 0.0% |
| 2015 Q2 | 5.55 Billion HKD | 0.0% |
| 2015 FY | 13.28 Billion HKD | 1.85% |
| 2015 Q4 | 7.72 Billion HKD | 0.0% |
| 2014 Q4 | 340.78 Million HKD | 53.85% |
| 2014 Q3 | 221.51 Million HKD | 0.0% |
| 2014 Q2 | 221.51 Million HKD | 0.0% |
| 2014 Q1 | 221.51 Million HKD | 0.0% |
| 2014 FY | 13.04 Billion HKD | 7.86% |
| 2013 Q3 | 111.37 Million HKD | 0.0% |
| 2013 FY | 12.09 Billion HKD | 0.0% |
| 2013 Q2 | 111.37 Million HKD | 0.0% |
| 2013 Q1 | 111.37 Million HKD | 0.0% |
| 2013 Q4 | 221.51 Million HKD | 98.88% |
| 2012 Q4 | 111.37 Million HKD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -120086.223% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | -660.342% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -82525.279% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -8193.74% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -171542.398% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | -4866.951% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | -2288.54% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | -5730.475% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -13450.486% |
| SSY Group Limited | 1.98 Billion HKD | -1381.987% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -17812.497% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -10115.551% |